Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 13/20 | 0.77 |
| ▸ | ATIC | P31939 | 4/20 | 0.60 |
| ▸ | FOLR2 | P14207 | 2/20 | 0.54 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.54 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 0.54 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lometrexol SCHEMBL18530 | 0.99 | GART (0.78) | GARTATICFOLR2FOLR1SLC46A1 | |
| Lometrexol SCHEMBL21248118 | 0.95 | GART (0.73) | GARTATICFOLR2FOLR1SLC46A1 | |
| Lometrexol SCHEMBL10067961 | 0.87 | GART (1.00) | GARTATIC | |
| Lometrexol SCHEMBL14469100 | 0.87 | GART (1.00) | GARTATIC | |
| Lometrexol SCHEMBL17520098 | 0.87 | GART (1.00) | GARTATIC | |
| Lometrexol SCHEMBL14365 | 0.87 | GART (1.00) | GARTATIC | |
| Lometrexol SCHEMBL3912 | 0.86 | GART (0.60) | GARTATICFOLR2FOLR1SLC46A1 | |
| SCHEMBL1065440 | 0.85 | GART (0.62) | GARTATICFOLR2FOLR1SLC46A1 | |
| SCHEMBL20659947 | 0.85 | GART (0.62) | GARTATICFOLR2FOLR1SLC46A1 | |
| SCHEMBL6829597 | 0.85 | GART (0.62) | GARTATICFOLR2FOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213577-A1 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-03 | — | — | US | disclosed |
| US-12246019-B2 | Alpha polyglutamated lometrexol and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240252498-A1 | GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2024-08-01 | — | — | US | disclosed |
| US-11771700-B2 | Gamma polyglutamated lometrexol and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210338675-A1 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2021-11-04 | — | — | US | disclosed |
| US-20210228581-A1 | GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2021-07-29 | — | — | US | disclosed |
| EP-3752157-A1 | GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3749312-A1 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019160734-A1 | GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019157121-A1 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246019-B2 | Alpha polyglutamated lometrexol and uses thereof | FPGS, PML, SYVN1 | GART 1418/4885ATIC 4000/4885FOLR2 83/4885 |
| US-11771700-B2 | Gamma polyglutamated lometrexol and uses thereof | IFNG, GGCT, FPGS | GART 1190/4885ATIC 3450/4885FOLR2 38/4885 |
| US-20250213577-A1 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | FPGS, PML, SYVN1 | GART 1418/4885ATIC 4000/4885FOLR2 83/4885 |
| US-20210228581-A1 | GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | IFNG, GGCT, FPGS | GART 1190/4885ATIC 3450/4885FOLR2 38/4885 |
| US-20210338675-A1 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | FPGS, PML, SYVN1 | GART 1418/4885ATIC 4000/4885FOLR2 83/4885 |
| US-20240252498-A1 | GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | IFNG, GGCT, FPGS | GART 1190/4885ATIC 3450/4885FOLR2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.